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a b s t r a c t
Objective: Genetic factors play a role in pathogenesis of amyotrophic lateral sclerosis (ALS). A
few studies demonstrated that the TT genotype of C677T polymorphism of the 5,10-
methylenetetrahydrofolate reductase (MTHFR) gene can increase the risk of sporadic
ALS. The aim of our study was to determine the relationship between C677T polymorphism
of MTHFR gene and the risk of sporadic ALS in Polish population and to perform the meta-
analysis assessing the significance this polymorphism for the risk of ALS in Caucasian
population.
Methods: We included 251 patients with ALS and 500 control subjects recruited from Polish
population and performed the meta-analysis of published data from Caucasian population.
MTHFR C677T polymorphism was genotyped using a TaqMan assay and 7900HT Fast real
Time PCR System.
Results: The frequency of genotypes did not differ significantly between Polish ALS patients
and control subjects (CC: 45.0 vs 45.8%, CT: 48.2 vs 45.0%, TT: 6.8 vs 9.2%, P = 0.46). The meta-
analysis including 863 ALS patients and 1362 controls revealed that TT genotype increases
the risk of sporadic ALS in Caucasian population.
Conclusion: Although we did not find the association between C677T polymorphism of
MTHRF gene and risk of ALS in Polish population, the results of meta-analysis suggest that
the TT genotype can be a genetic risk factor for ALS in Caucasian population.
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MTHFR C677T polymorphism in sporadic ALS cases and
controls.
ALS (n = 251) Controls (n = 500) P
Genotype
CC 113 (45.0%) 229 (45.8%) 0.46
TC 121 (48.2%) 225 (45.0%)
TT 17 (6.8%) 46 (9.2%)
Recessive model (TT vs TC + CC)
OR: 1.39, 95% CI: 0.78–2.50
0.26
Dominant model (TT + TC vs CC)
OR: 0.97, 95% CI: 0.70–1.35
0.85
Allele
C 234 (93.2%) 453 (90.6%) 0.22
OR: 0.70, 95% CI: 0.39–1.28
T 139 (55.4%) 271 (54.2%) 0.75
OR: 0.95, 95% CI: 0.71–1.281. Introduction
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative
disease of unknown etiology [1]. Both the genetic and the
environmental factors play a role in pathogenesis of this
disease [2].
The elevated homocysteine plasma level can lead to
neurodegeneration due to the impairment of DNA repairing
ability, excitotoxicity, oxidative stress, energy metabolism
disturbances and enhancement of the b-amyloid toxicity [3–5].
The plasma homocysteine level depends on the genetic and
environmental factors [6,7]. The most common genetic risk
factor for hyperhomocysteinemia is the C677T polymorphism
of the 5,10-methylenetetrahydrofolate reductase (MTHFR)
gene [6,8]. The TT variant of this gene is associated with
elevated plasma homocysteine levels [7,8].
The results of the genetic studies assessing the association
between the MTHFR gene polymorphisms and the risk of ALS
are not consistent. The TT genotype of the MTHFR gene was
associated with the increased risk of ALS in German and Swiss
population (OR: 2.26, 95% CI: 1.03–4.97) [9]. Sayci et al. have
found that C677T polymorphism is a genetic risk factor for
sporadic ALS in women (OR: 2.56, 95% CI: 1.14–5.74) [10]. On
contrary, the study conducted in the Italian population did
not show the association between C677T polymorphism and
the risk of the sporadic form of ALS (OR: 0.87, 95% CI: 0.73–1.03)
[11].
The aim of our study was to determine the relationship
between C677T polymorphism of MTHFR gene and the risk of
sporadic ALS in Polish population and to perform the meta-
analysis assessing the significance this polymorphism for the
risk of ALS in Caucasian population.
2. Material and methods
The patients to this study were recruited from ALS patients
diagnosed at the Department of Neurology, University Hospi-
tal, Kraków, Poland, between 1999 and 2011. All included
patients fulfilled the El Escorial criteria of definite or probable
sporadic ALS [12,13]. Control subjects were recruited from
relatives of the hospital staff, spouses of the patients, and
patients hospitalized at the University Hospital for the non-
neurological disorders. We included 251 patients with ALS and
500 control subjects. Eighty-four (33.5%) ALS patients had
bulbar onset and 167 (66.5%) had limb onset. The mean age did
not differ between ALS patients and controls (57.7  12.1 vs
57.9  12.6 years respectively, P = 0.87). The proportion of
woman was similar in both groups (50.2% of ALS patients vs
50.6% controls, P = 0.92). All participants were of Caucasian
origin. Informed consent was given by all participants before
the inclusion to the study. The Bioethics Committee approved
the study protocol.
From all participants 5 ml of peripheral blood was collected.
Genomic DNA was immediately extracted from blood using a
commercially available kit from QIAGEN QIAamp® DNA Mini.
MTHFR C677T polymorphism was genotyped using a TaqMan
assay (Applied Biosystems, Carlsbad, CA, USA) and 7900HT
Fast Real Time PCR System (Applied Biosystems).Differences between groups were determined using the
unpaired Student's t-test (continuous variables) or chi-
squared test (categorical variables). Hardy-Weinberg equilib-
rium was tested using the chi-squared test. The association of
the MTHFR genotypes with ALS was tested using logistic
regression analysis under assumption of recessive (CC vs
CT + TT) or dominant (CC + CT vs TT) effect for the T allele.
P value <0.05 was considered statistically significant.
To identify the relevant studies for the meta-analysis, we
searched the Medline until August 2014 using the following
key words: MTHFR, C677T, polymorphism, amyotrophic lateral
sclerosis, and we checked references from retrieved articles.
We include only studies conducted in Caucasian population
and published in English.
The meta-analysis and heterogeneity analysis were per-
formed using Review Manager version 5.0 (Copenhagen, The
Nordic Cochrane Centre, The Cochrane Collaboration). A
pooled odds ratio (OR) and 95% confidence intervals were
calculated using fixed-effect models.
3. Results
Genotypes distribution in studied groups is shown in Table 1.
Genotypes distribution in control group was in Hardy-
Weinberg equilibrium (x2 = 0.77; P = 0.38), but it deviates from
Hardy-Weinberg equilibrium in ALS patients (x2 = 4.2; P = 0.06).
The frequency of alleles and genotypes did not differ
significantly between ALS patients and control subjects. The
sub-analysis including only men or only patients with bulbar
onset did not reveal differences in genotypes distribution
between groups.
For meta-analysis we identified two studies investigated
the association between the MTHFR C677T gene polymor-
phism and risk of ALS in Caucasian population. The German-
Swiss study compromised 162 ALS patients (33% female, 67%
limb onset, mean age: 60 years) and 162 controls (39% female,
mean age: 59 years) [10]. The Italian study included 450 ALS
patients (53% female, 69.9% spinal onset, mean age: 61.8 years)
and 700 controls (55.6% female, mean age: 60.9 years) [11].
Fig. 1 – The association between MTHFR gene polymorphism and the risk of ALS: (A) CC + TC vs TT genotypes,
(B) CC vs TC + TT genotypes and (C) C allele vs T allele.
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risk of sporadic ALS in Caucasian population (Fig. 1).
4. Discussion
We did not find the association between the MTHFR C677T
polymorphism and the risk of ALS in Polish population. The
obtained negative results can be due to low statistical power of
our study and rare frequency of TT genotype in the Polish
population.
The meta-analysis including our data and the results of two
other studies conducted on Caucasian population revealed
that the TT genotype could be the risk factor for sporadic ALS,
although significant heterogeneity was observed between the
studies. Previous studies demonstrated that the TT genotype
of the MTHFR gene could be the genetic risk factor not only for
ALS [9,11], but also for other neurodegenerative disorders such
as Alzheimer disease or Parkinson disease [14,15]. It suggests
that there is a common pathomechanism linking MTHFR
C677T polymorphism with neurodegeneration.MTHFR is a folate-dependent enzyme that catalyzes
remethylation of homocysteine. The TT genotype of MTHRF
gene is associated with reduced enzymatic activity resulting in
mild hyperhomocysteinemia [16]. Homocysteine exerts direct
neurotoxic effects. In vivo, administration of the glutamate DL-
homocysteic acid to rat spinal cord disrupts calcium homeo-
stasis and leads to degeneration of motor neurons [17].
Homocysteine-induced cytotoxicity was observed in motor
neuronal cell line transfected with mutant form (A4V) of Cu,
Zn-superoxide dismutase (SOD1) [18]. In this model neurotoxic
effect of homocysteine was inhibited by the antioxidant trolox
and copper chelator bathocuproinedisulfonate. Using SOD1
(G93A) mice model of ALS, Zhang et al. demonstrated that
mutation in SOD1 causes a significant increase in plasma
homocysteine level and folic acid treatment significantly
delays the disease onset and reduces motor neuron loss [19].
Homocysteine activate N-methyl D-aspartate receptors in-
creasing the inhibitory effect of oxidative stress [20]. Hyper-
homocysteinemia increases also beta-amyloid production in
rat brain by enhancing gamma-secretase and phosphorylation
of amyloid precursor protein [21].
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out to be causal, then lowering homocysteine level should
reduce ALS incidence. It was shown that in ALS patients
homocysteine plasma and cerebrospinal fluid level is elevated
[22–24]. Reduction of 3–4 mmol/L in total homocysteine levels
can be achieved by treatment with folic acid and vitamin B12
[25]. Vitamin B12 decreased homocysteine-induced motor
neuron death in vitro via reduction in caspase activation [26].
It was also shown that dietary folate modification effect
between MTHFR genotype, homocysteine and stroke risk was
absented of benefit in populations with increasing folate intake
[27], suggesting that similar impact may be seen in ALS patients.
To conclude, the results of meta-analysis suggest that the
TT polymorphism of MTHFR gene could be the risk factor for
sporadic ALS in Caucasian population. This association
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